Prime Capital Investment Advisors LLC Has $307,000 Stock Holdings in Fulgent Genetics, Inc. (NASDAQ:FLGT)

Prime Capital Investment Advisors LLC trimmed its position in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 32.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,627 shares of the company’s stock after selling 5,005 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Fulgent Genetics were worth $307,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of FLGT. Covington Capital Management raised its holdings in Fulgent Genetics by 133.3% during the 3rd quarter. Covington Capital Management now owns 700 shares of the company’s stock worth $27,000 after buying an additional 400 shares during the period. Geneos Wealth Management Inc. raised its holdings in Fulgent Genetics by 416.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 491 shares of the company’s stock worth $30,000 after buying an additional 396 shares during the period. Asset Management One Co. Ltd. acquired a new stake in Fulgent Genetics during the 3rd quarter worth approximately $34,000. Covestor Ltd raised its holdings in Fulgent Genetics by 48.0% during the 3rd quarter. Covestor Ltd now owns 1,508 shares of the company’s stock worth $40,000 after buying an additional 489 shares during the period. Finally, Lazard Asset Management LLC acquired a new stake in Fulgent Genetics during the 4th quarter worth approximately $46,000. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Piper Sandler dropped their target price on shares of Fulgent Genetics from $28.00 to $25.00 and set a “neutral” rating on the stock in a report on Wednesday, March 6th.

Fulgent Genetics Stock Down 1.4 %

Shares of FLGT opened at $20.78 on Friday. The stock has a market capitalization of $621.32 million, a P/E ratio of -3.68 and a beta of 1.43. Fulgent Genetics, Inc. has a twelve month low of $20.62 and a twelve month high of $44.09. The company has a 50 day moving average of $23.14 and a 200-day moving average of $25.58.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.61. The company had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $67.14 million. Fulgent Genetics had a negative net margin of 58.03% and a negative return on equity of 3.04%. On average, sell-side analysts anticipate that Fulgent Genetics, Inc. will post -2.04 earnings per share for the current fiscal year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.